Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00518700 · ClinicalTrials.gov registry record · Phase 4
Comfort Evaluation of a New MPS vs. Replenish in Contact Lens Patients
A Phase 4 study, sponsored by Innovative Medical.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT00518700: Completed Phase 4 study, sponsored by Innovative Medical.
NCT00518700 is a Phase 4 study that has completed, run by Innovative Medical. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00518700, a Phase 4 study, has completed, sponsored by Innovative Medical.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
To compare corneal staining after contact lens instillation with a new MPS vs. RepleniSH
Interventions
- OTHER new MPS
- OTHER RepleniSH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
What the finished NCT00518700 record still lists
NCT00518700 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which new MPS is the first listed.
NCT00518700 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00518700 about?
NCT00518700 is a clinical study titled "Comfort Evaluation of a New MPS vs. Replenish in Contact Lens Patients". To compare corneal staining after contact lens instillation with a new MPS vs. RepleniSH
What is the current status of trial NCT00518700?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00518700?
The interventions under investigation include: new MPS (OTHER), RepleniSH (OTHER).
Who is sponsoring clinical trial NCT00518700?
This trial is sponsored by Innovative Medical, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00518700's enrollment target sits among peer trials
24 1699th of 2000 higher than 276 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant